ADAGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Adagene Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026
$2.29+0.23 (+11.17%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Apr 1, 2026 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 12, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 24, 2025 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 25, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Jan 16, 2024 | After market close | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 31, 2023 | Before market open | $17.30M | $-0.08 | $0.00 |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 28, 2023 | After market close | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 31, 2022 | Before market open | – | – | – |
Press releases
Announcements Adagene filed with the SEC
Adagene Announces NMPA Clearance of Investigational
EX-99.1 to Form 6-K
Adagene Announces that Third Arc Bio Has Selected
EX-99.1 to Form 6-K
Adagene Achieves Milestone in Collaboration
EX-99.1 to Form 6-K
INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.2 to Form 6-K
Adagene Presents Two Posters at AACR 2026 with
EX-99.1 to Form 6-K
of US$70.0 Million Public Offering of ADSs
EX-99.1 to Form 6-K
Adagene Announces Clinical Collaboration with
EX-99.1 to Form 6-K
Updated Data from Phase 1b/2 Study of Muzastotug
EX-99.2 to Form 6-K
Reports Full Year 2025 Financial Results and Provides Corporate Update
EX-99.1 to Form 6-K
Adagene Provides Business Update and 2026 Objectives
EX-99.1 to Form 6-K
Adagene Announces Licensing Agreement with
EX-99.1 to Form 6-K
INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.2 to Form 6-K
Regulatory Update on Clinical Development Plan for
EX-99.1 to Form 6-K
Adagene announces up to $25 million strategic
EX-99.1 to Form 6-K
Adagene Reports Full Year 2024 Financial Results
EX-99.1 to Form 6-K
Adagene Announces Updated Data from Phase 1b/2
EX-99.1 to Form 6-K
INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
EX-99.2 to Form 6-K
Adagene Reports Full Year 2023 Financial Results
EX-99.1 to Form 6-K
ADG126 MSS CRC Clinical Results
EX-99.2 to Form 6-K
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic
EX-99.1 to Form 6-K
Adagene Reports Six Month Financial Results
EX-99.1 to Form 6-K
Adagene Announces Updates to its Board of Directors
EX-99.1 to Form 6-K
Adagene Reports Full Year 2022 Financial Results
EX-99.1 to Form 6-K
Adagene Appoints Cuong Do to Board of Directors
EX-99.1 to Form 6-K
Adagene Reports Financial Results for the Six
EX-99.1 to Form 6-K
of Share Repurchase Program up to US$10 Million
EX-99.1 to Form 6-K